Drug Trial Radar · NCT05899816
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
Jun 7, 2023
Primary completion
Aug 26, 2024
Study completion Nov 14, 2024
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jun 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 54 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to: * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24
Conditions
- Atopic Dermatitis
- Moderate-to-severe Atopic Dermatitis
Interventions
RocatinlimabDrug
Subcutaneous (SC) injection
PlaceboDrug
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Positive Anti-tetanus Response at Week 24Time frame: Week 20 to Week 24
- Percentage of Participants With a Positive Anti-meningococcal Response at Week 24Time frame: Week 20 to Week 24
Locations
85 sites in 2 countries. Site status is shown where the registry gives one.
Affiliated Dermatology
Scottsdale, Arizona
Center for Dermatology and Plastic Surgery
Scottsdale, Arizona
Scottsdale Clinical Trials
Scottsdale, Arizona
Medical Advancement Centers of Arizona
Tempe, Arizona
Little Rock Allergy and Asthma Clinical Research Center
Little Rock, Arkansas
Kern Research Inc
Bakersfield, California
Hope Clinical Research LLC
Canoga Park, California
Doc1 Healthcare Systems
Chino, California
310 Clinical Research
Inglewood, California
Chemidox Clinical Trials Incorporated
Lancaster, California
Long Beach Research Institute
Long Beach, California
University of California Los Angeles
Los Angeles, California
Wallace Medical Group Inc
Los Angeles, California
West Los Angeles Clinical Trials
Los Angeles, California
Northridge Clinical Trials
Northridge, California
Havana Research Institute Inc
Pasadena, California
Peninsula Research Associates
Rolling Hills Estates, California
Integrative Skin Science and Research
Sacramento, California
Wake Research Medical Center for Clinical Research
San Diego, California
Cura Clinical Research
Sherman Oaks, California
Wolverine Clinical Trials
Tustin, California
Alliance for Multispecialty Research
Coral Gables, Florida
Life Clinical Trials
Coral Springs, Florida
AllerVie Clinical Research- Destin
Destin, Florida
D and H Doral Research Centers
Doral, Florida
Saint Jude Clinical Research
Doral, Florida
Direct Helpers Research Center
Hialeah, Florida
Nexus Clinical Research
Homestead, Florida
D and H National Research Centers
Miami, Florida
Gold Coast Health Research Center
Miami, Florida
Anchor Medical Research
Miami, Florida
Meridian International Research
Miami Gardens, Florida
AllerVie Clinical Research- Ocala
Ocala, Florida
D and H Tamarac Research Centers
Tamarac, Florida
Hamilton Research, LLC
Alpharetta, Georgia
Divine Dermatology and Aesthetics
Atlanta, Georgia
MetroDerm / Atlanta Center for Clinical Research, LLC
Atlanta, Georgia
First Georgia Physicians Group
Fayetteville, Georgia
Dermatologic Surgery Specialists
Macon, Georgia
McIntosh Clinic PC
Thomasville, Georgia
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.